AstraZeneca PLC (AZN)'s Thyroid Cancer Drug Caprelsa Gets EU Approval  
2/21/2012 7:44:11 AM

British drug maker AstraZeneca Plc (AZN: News ,AZN.L: News ) on Tuesday said the European Commission has granted marketing authorisation for Caprelsa (vandetanib). This is for the treatment of aggressive and symptomatic medullary thyroid cancer or MTC in patients with unresectable locally advanced or metastatic disease. The company noted that the drug, a prescription oral kinase inhibitor treatment, is the first approved treatment for advanced MTC in Europe. The marketing authorisation of CAPRELSA is based on data from the Phase III CAPRELSA clinical trial program, including the ZETA study.